Curonix LLC Announces Expanded Reimbursement Coverage for Freedom® Peripheral Nerve Stimulator (PNS) System, Providing Access To An Additional 27 Million Covered Lives NationwidePOMPANO BEACH, Fla., April 02, 2026 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company dedicated to relieving chronic pain, today announced significant reimbursement milestones for its Freedom® Peripheral Nerve Stimulator (PNS) System, expanding access to a clinically validated, permanent non-opioid treatment option for chronic pain management.
Curonix LLC Announces Commercial Availability of the Freedom® Peripheral Nerve Stimulator (PNS) System as the Only Full-Body PNS Therapy Available in the United States for Craniofacial PainPOMPANO BEACH, Fla., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company dedicated to relieving chronic pain, today announced the commercial availability of the Freedom® PNS System for the treatment of chronic craniofacial pain. Freedom PNS is now the first and only PNS System in the United States available for this indication and supported by data from an FDA-approved Investigational Device Exemption (IDE) clinical study, allowing a greater patient population to benefit from PNS therapy.
Curonix Publishes Results for the First and Only IDE PNS Multi-Center Randomized Clinical Trial Resulting in an FDA 510(k) Expanded Indication for Treating Chronic Craniofacial PainPOMPANO BEACH, Fla., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Curonix LLC, a leader in non-opioid neuromodulation therapies for the treatment of chronic pain, today announced the publication of its landmark prospective, multi-center, randomized, FDA-approved IDE clinical trial (RCT) for chronic craniofacial pain in Pain Physician.
Curonix Strengthens Executive Leadership with Appointment of Leading Medical Device Executive Russell Fleeger as Chief Financial Officer to Drive Next Stage of GrowthPOMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Curonix LLC (“Curonix” or the “Company”), a medical technology company dedicated to developing and commercializing innovative therapies to relieve chronic pain, today announced the appointment of Russell Fleeger as Chief Financial Officer, effective immediately. Bringing more than 25 years of global finance experience, including two decades in the medical device industry, Fleeger joins Curonix to help lead the Company into its next phase of growth and strategic expansion.A proven financial and operational leader, Fleeger most recently served as the CFO of Franklin Electric Co., Inc.'s largest segment, a publicly traded industrial manufacturing organization. Before joining Franklin Electric, he spent 18 years at Biomet and Zimmer Biomet Holdings, Inc., where he advanced through a series of finance and commercial leadership roles, including serving as Global CFO for the Spine, CMFT & Robotic division. During his tenure, Fleeger also spent nearly seven years in Japan overseeing financial and strategy operations as the Asia Pacific CFO for Orthopedic and other businesses, as well as VP, APAC Integration & Strategy. Mr. Fleeger holds an MBA in Finance from the Kelley School of Business at Indiana University and a BA in Economics from Valparaiso University. “Curonix is at an exciting inflection point, one defined by purpose and possibility,” said Fleeger. “I’m honored to work with a team so deeply committed to transforming how chronic pain is treated. I joined the organization to help take Curonix into its next phase by transforming and scaling the neurostimulation business model, while optimizing operations to support the growth of the Company’s PNS therapy.”
Curonix Expands the Freedom® PNS System Patient Treatment Options with the Launch of its Innovative Wearable Solution for Chronic Pain of the Head, Neck, Shoulder, and TorsoPOMPANO BEACH, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company specializing in opioid-free chronic pain relief, today announced the launch of its next-generation wearable accessory for the Freedom® Peripheral Nerve Stimulator (PNS) System. This innovative wearable targets chronic pain in the head, neck, shoulder, and upper torso regions, with the potential to serve up to 235,000 patients annually1.
Curonix Unveils NervPulse™ Therapy: Setting a New Standard in Nerve-Specific Peripheral Nerve Stimulation (PNS) TherapyPOMPANO BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company specializing in relieving chronic pain without the use of opioids, proudly introduces NervPulse™ Therapy, an advanced, evidence-based programming platform designed to optimize peripheral nerve stimulation (PNS) therapy with the Freedom® PNS System. By delivering precise, nerve-specific stimulation, NervPulse Therapy sets a new standard in patient care, intending to improve clinical results and transform the patient experience.NervPulse Therapy is built from a robust clinical foundation of over 20,000 Freedom PNS procedures* and incorporates long-term data from 13 peer-reviewed publications and 450+ study patients. This extensive real-world and clinical experience has been transformed into an advanced, evidence-based solution developed in collaboration with leading physicians. By leveraging deep insights, NervPulse Therapy delivers standardized therapy programs for 26 individual peripheral nerves, enabling providers to implement the therapy with precision. These data-driven programs are designed to optimize device performance, improve procedural efficiency, and, most importantly, maximize patient outcomes by ensuring consistent, reproducible, and long-lasting therapeutic results and benefits."At Curonix, we are committed to redefining the boundaries of chronic pain management through innovation and evidence-based solutions," said Aure Bruneau, Chief Executive Officer of Curonix. "NervPulse Therapy is a transformative advancement in peripheral nerve stimulation, leveraging real-world data and clinical excellence to deliver targeted therapy. This approach enhances precision and efficiency for providers but, most importantly, it is intended to elevate the quality of treatment for patients suffering from chronic pain, today. NervPulse Therapy represents a major step forward in our mission to deliver innovative, life-changing relief for chronic pain patients."With NervPulse Therapy, Curonix continues to advance the field of PNS therapy by delivering targeted, nerve-specific programming that enhances outcomes and transforms the patient experience.
Curonix leads the PNS market with expanded MR Labeling for 3T Full-Body MRI Scans for its Freedom® Peripheral Nerve Stimulator (PNS) SystemPOMPANO BEACH, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company specializing in relieving chronic pain without the use of opioids, is proud to announce the expansion of MR labeling for its Freedom® Peripheral Nerve Stimulator (PNS) System to include full-body 3T MRI scans. The Freedom PNS System is the only PNS system cleared for applications throughout the entire body. Today, the Freedom PNS System is also the first and only permanent PNS system in the United States that is MR Conditional with the ability to scan throughout the body and over the implanted device at both 1.5T and 3T.* This marks another significant milestone in transforming the boundaries of chronic pain management by providing patients broader access to diagnostic imaging.
Curonix Foundational Clinical Data Published Within the American Society of Interventional Pain Physicians (ASIPP) Peripheral Nerve Stimulation Guidelines for the Management of Chronic PainPOMPANO BEACH, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Today, Curonix LLC highlights the newly released evidence-based consensus guidelines from the American Society of Interventional Pain Physicians (ASIPP®) validating the importance of PNS as a standard of care for chronic pain management, to optimize long-term patient outcomes.
Curonix Receives the First Full-Body Peripheral Nerve Stimulator (PNS) FDA Clearance, including Craniofacial Pain Indication, for its Freedom® PNS SystemPOMPANO BEACH, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to relieving chronic pain without the use of opioids, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to expand the labeled indications for its minimally-invasive Freedom Peripheral Nerve Stimulator (PNS) System to include the craniofacial region. This makes Freedom PNS the first and only system cleared for full-body permanent PNS for the treatment of chronic, intractable pain of peripheral nerve origin.
Curonix Partners with Sure Med Compliance to Expand PNS Clinical EvidencePOMPANO BEACH, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to easing chronic pain without the use of opioids, and Sure Med Compliance, a digital healthcare company focused on curbing opioid-related overdoses, announced today an exclusive partnership for large-scale, long-term PNS clinical data collection using Sure Med’s Perspectives in Care digital health platform.
Curonix Celebrates 1st AnniversaryPOMPANO BEACH, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Today, Curonix LLC, a leading peripheral nerve stimulation company celebrated its first anniversary. In November 2022, Curonix completed the purchase of substantially all assets, excluding liabilities, of Stimwave Technologies. During its first 12 months, Curonix:
Retrospective clinical study highlights the effectiveness of Curonix’s Freedom® PNS System in reducing pain scores and improving patient satisfactionPOMPANO BEACH, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to freeing patients from chronic pain, announced the publication of a retrospective study in Neuromodulation reviewing the effectiveness of the Freedom® Peripheral Nerve Stimulator (PNS) System at the posterior tibial nerve for treating chronic foot pain related to peripheral neuropathy. The results showed that the Freedom PNS System successfully reduced pain scores and improved patient satisfaction. Patients also reported a considerable improvement in mobility and quality of life.
Curonix Provides Reimbursement Update on Neurostimulator Procedure CodesPOMPANO BEACH, Fla., July 18, 2023 (GLOBE NEWSWIRE) -- Today, Curonix LLC provided an update on the Medicare Physician Fee Schedule Proposed Rule published by the Centers for Medicare & Medicaid Services (CMS) on July 13, 2023, that provides additional coding clarity and positive proposed Medicare reimbursement rate updates.
